Adicet Bio, Inc. (ACET)Healthcare | Biotechnology | Boston, United States | NasdaqCM
4.96 USD
-0.15
(-2.935%) ⇩
(Oct. 14, 2026, 12:14 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:48 a.m. EDT
The investment case for Adicet Bio is effectively broken. The company is trapped in a multi-year freefall, having lost 98.8% of its value over the last seven years, with the last three years showing consecutive negative returns. Despite a 'strong buy' analyst recommendation and a lofty $90 price target, these figures are disconnected from reality given the negative earnings, massive cash burn, and deteriorating fundamentals. The balance sheet is fragile with negative free cash flow and significant debt relative to equity. Crucially, the options market confirms the bearish thesis, with traders pouring capital into deep out-of-the-money puts rather than calls, signaling a high probability of continued collapse. There is no dividend to provide income, and the recent price action shows no sign of a recovery, trading well below its 50-day moving average. This is a speculative trap disguised by optimistic analyst notes. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.091088 |
| AutoARIMA | 0.091351 |
| AutoETS | 0.098621 |
| MSTL | 0.098727 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 3.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.699 |
| Market Cap | 46,432,992 |
| Forward P/E | -1.23 |
| Beta | 1.63 |
| Website | https://www.adicetbio.com |
As of Oct. 10, 2026, 6:48 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes 7.5 and 10.0) compared to negligible call volume. While there is some call activity at distant strikes (17.5), the overwhelming weight of the options chain is on the put side, indicating a strong consensus expectation of further price declines.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.67609024 |
| Address1 | 131 Dartmouth Street |
| Address2 | 3rd Floor |
| All Time High | 2,362.864 |
| All Time Low | 5.1 |
| Ask | 5.85 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 217,710 |
| Average Daily Volume3 Month | 178,087 |
| Average Volume | 178,087 |
| Average Volume10Days | 217,710 |
| Beta | 1.627 |
| Bid | 5.04 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 11.161 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.96 |
| Current Ratio | 6.709 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 5.27 |
| Day Low | 4.96 |
| Debt To Equity | 10.699 |
| Display Name | Adicet Bio |
| Dividend Date | 1,600,214,400 |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -98,121,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.513 |
| Enterprise Value | -50,330,308 |
| Eps Current Year | -6.35833 |
| Eps Forward | -4.04 |
| Eps Trailing Twelve Months | -10.42 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.2912 |
| Fifty Day Average Change | -3.3311996 |
| Fifty Day Average Change Percent | -0.40177536 |
| Fifty Two Week Change Percent | -67.609024 |
| Fifty Two Week High | 17.04 |
| Fifty Two Week High Change | -12.080001 |
| Fifty Two Week High Change Percent | -0.7089202 |
| Fifty Two Week Low | 4.96 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 4.96 - 17.04 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,516,977,000,000 |
| Float Shares | 7,434,487 |
| Forward Eps | -4.04 |
| Forward P E | -1.2277228 |
| Free Cashflow | -47,516,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 102 |
| Fullday Change | -0.1500001 |
| Fullday Change Percent | -2.9354224 |
| Fullday Price | 4.96 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.010779999 |
| Held Percent Institutions | 0.64715 |
| Implied Shares Outstanding | 9,361,490 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,767,052,800 |
| Last Split Factor | 1:16 |
| Long Business Summary | Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts. |
| Long Name | Adicet Bio, Inc. |
| Market | us_market |
| Market Cap | 46,432,992 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_310073311 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -98,974,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 78,917,360 |
| Number Of Analyst Opinions | 6 |
| Open | 5.1 |
| Operating Cashflow | -84,529,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 503 9095 |
| Previous Close | 5.11 |
| Price Eps Current Year | -0.78007907 |
| Price Hint | 4 |
| Price To Book | 0.4444046 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.59 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.1500001 |
| Regular Market Change Percent | -2.9354224 |
| Regular Market Day High | 5.27 |
| Regular Market Day Low | 4.96 |
| Regular Market Day Range | 4.96 - 5.27 |
| Regular Market Open | 5.1 |
| Regular Market Previous Close | 5.11 |
| Regular Market Price | 4.96 |
| Regular Market Time | 1,791,994,448 |
| Regular Market Volume | 163,166 |
| Return On Assets | -0.41665 |
| Return On Equity | -0.78083 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 9,361,490 |
| Shares Percent Shares Out | 0.0519 |
| Shares Short | 485,466 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 252,663 |
| Short Name | Adicet Bio, Inc. |
| Short Percent Of Float | 0.051999997 |
| Short Ratio | 1.67 |
| Source Interval | 15 |
| State | MA |
| Symbol | ACET |
| Target High Price | 90.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 34.83333 |
| Target Median Price | 24.0 |
| Total Cash | 118,190,000 |
| Total Cash Per Share | 10.98 |
| Total Debt | 12,854,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.94886 |
| Two Hundred Day Average Change | -2.9888601 |
| Two Hundred Day Average Change Percent | -0.37601116 |
| Type Disp | Equity |
| Volume | 163,166 |
| Website | https://www.adicetbio.com |
| Zip | 2,116 |